Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TK1 | P04183 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802542 | 1.00 | POLB (0.55) | POLBTK1BCHETOP2A | |
| Methyl Phosphonate SCHEMBL8882994 | 0.96 | POLB (0.58) | POLBTK1 | |
| SCHEMBL16948012 | 0.91 | BCHE (0.49) | POLBTK1BCHETOP2A | |
| SCHEMBL12371808 | 0.91 | BCHE (0.49) | POLBTK1BCHETOP2A | |
| SCHEMBL13026817 | 0.90 | LMNA (0.58) | — | |
| SCHEMBL22977550 | 0.90 | TK1 (0.58) | TK1BCHE | |
| SCHEMBL20810641 | 0.90 | TK1 (0.58) | TK1BCHE | |
| SCHEMBL8188889 | 0.89 | TK1 (0.62) | TK1TOP2A | |
| SCHEMBL7623504 | 0.89 | TK1 (0.62) | TK1TOP2A | |
| SCHEMBL8188888 | 0.89 | TK1 (0.62) | TK1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4762823-A | VIRICIDES, ANTICARCINOGENIC AGENTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1988-08-09 | — | — | US | claimed |
| EP-0222192-A2 | Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil | Sloan-Kettering Institute For Cancer Research (US) | 1987-05-20 | — | — | EP | claimed |
| US-20230332197-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | ILLUMINA, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-04-20 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | LG ELECTRONICS INC. (KR) | 2022-04-28 | — | — | US | disclosed |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| WO-1996010030-A1 | OLIGOMERS HAVING HETEROATOM-LINKED CONJUGATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| US-5489677-A | NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022886-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-4762823-A | VIRICIDES, ANTICARCINOGENIC AGENTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1988-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119408-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | NUDT1, PNP, NT5C2 | POLB 73/4885TK1 75/4885BCHE 2467/4885 |
| US-20220127299-A1 | NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF | NUDT21, CPSF7, DCLRE1A | POLB 24/4885TK1 92/4885BCHE 1777/4885 |
| US-20230332197-A1 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | NT5C3B, NSUN2, DUT | POLB 42/4885TK1 132/4885BCHE 2640/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | POLB 2/4885TK1 98/4885BCHE 2764/4885 |
| US-10822653-B1 | Nucleotide cleavable linkers and uses thereof | NUDT21, CPSF7, DCLRE1A | POLB 24/4885TK1 92/4885BCHE 1777/4885 |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | POLB 2/4885TK1 98/4885BCHE 2764/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | POLB 2/4885TK1 98/4885BCHE 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.